• Defining the minimal dataset that aligns with both regulatory and payor requirements while maintaining feasibility in early access settings

• Addressing variability in RWD collection across EU countries and navigating differing expectations from regulators and health technology assessment (HTA) bodies

• Overcoming data collection limitations in different EAP models, from named-patient programmes to broader early access frameworks